Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery

被引:32
|
作者
Lai, Xianyin [1 ]
Tang, Jason [1 ]
ElSayed, Mohamed E. H. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Biotechnol Discovery Res, Indianapolis, IN 46285 USA
关键词
Proteolytic stability; peptide; protein; antibody; peptidase; cleavage site; amino acid replacement; GLUCAGON-LIKE PEPTIDE-1; COLONY-STIMULATING FACTOR; BETA-AMINO ACIDS; SUBSTRATE-SPECIFICITY; ASYMMETRIC-SYNTHESIS; RECEPTOR AGONISTS; SALMON-CALCITONIN; ORAL ABSORPTION; ACTIVE-SITE; DEGRADATION;
D O I
10.1080/17460441.2021.1942837
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: To discover and develop a peptide, protein, or antibody into a drug requires overcoming multiple challenges to obtain desired properties. Proteolytic stability is one of the challenges and deserves a focused investigation. Areas covered: This review concentrates on improving proteolytic stability by engineering the amino acids around the cleavage sites of a liable peptide, protein, or antibody. Peptidases are discussed on three levels including all peptidases in databases, mixtures based on organ and tissue types, and individual peptidases. The technique to identify cleavage sites is spotlighted on mass spectrometry-based approaches such as MALDI-TOF and LC-MS. For sequence engineering, the replacements that have been commonly applied with a higher chance of success are highlighted at the beginning, while the rarely used and more complicated replacements are discussed later. Although a one-size-fits-all approach does not exist to apply to different projects, this review provides a 3-step strategy for effectively and efficiently conducting the proteolytic stability experiments to achieve the eventual goal of improving the stability by engineering the molecule itself. Expert opinion: Improving the proteolytic stability is a spiraling up process sequenced by testing and engineering. There are many ways to engineer amino acids, but the choice must consider the cost and properties affected by the changes of the amino acids.
引用
收藏
页码:1467 / 1482
页数:16
相关论文
共 50 条
  • [41] Recent advances in cancer drug discovery targeting RAS
    Wilson, Candice Y.
    Tolias, Peter
    DRUG DISCOVERY TODAY, 2016, 21 (12) : 1915 - 1919
  • [42] Recent Advances in Prostate Cancer Treatment and Drug Discovery
    Nevedomskaya, Ekaterina
    Baumgart, Simon J.
    Haendler, Bernard
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
  • [43] Massive protein search advances drug discovery
    Studt, T
    R&D MAGAZINE, 1998, 40 (09): : 71 - 71
  • [44] Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates
    Matsuda, Yutaka
    Mendelsohn, Brian A.
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2021, 69 (10) : 976 - 983
  • [45] Recent advances in computational prediction of drug absorption and permeability in drug discovery
    Hou, Tingjun
    Wang, Junmei
    Zhang, Wei
    Wang, Wei
    Xu, Xiaojie
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (22) : 2653 - 2667
  • [46] Antibody-drug conjugates: Recent advances in payloads
    Wang, Zhijia
    Li, Hanxuan
    Gou, Lantu
    Li, Wei
    Wang, Yuxi
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (10) : 4025 - 4059
  • [47] Antibody-drug conjugates: Recent advances in payloads
    Zhijia Wang
    Hanxuan Li
    Lantu Gou
    Wei Li
    Yuxi Wang
    Acta Pharmaceutica Sinica B, 2023, (10) : 4025 - 4059
  • [48] Recent advances in the construction of antibody-drug conjugates
    Chudasama, Vijay
    Maruani, Antoine
    Caddick, Stephen
    NATURE CHEMISTRY, 2016, 8 (02) : 113 - 118
  • [49] Recent Advances in Antibody-Drug Conjugates for Lymphoma
    Russler-Germain, David A.
    Kahl, Brad S.
    ONCOLOGY-NEW YORK, 2020, 34 (12): : 522 - +
  • [50] Recent advances of antibody drug conjugates for clinical applications
    Pengxuan Zhao
    Yuebao Zhang
    Wenqing Li
    Christopher Jeanty
    Guangya Xiang
    Yizhou Dong
    Acta Pharmaceutica Sinica B, 2020, 10 (09) : 1589 - 1600